538 related articles for article (PubMed ID: 28561071)
1. Clinical utility of gene-expression signatures in early stage breast cancer.
Kwa M; Makris A; Esteva FJ
Nat Rev Clin Oncol; 2017 Oct; 14(10):595-610. PubMed ID: 28561071
[TBL] [Abstract][Full Text] [Related]
2. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
3. Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
Chia SKL
Curr Oncol; 2018 Jun; 25(Suppl 1):S125-S130. PubMed ID: 29910655
[TBL] [Abstract][Full Text] [Related]
4. Gene-Expression-Based Predictors for Breast Cancer.
Gupta A; Mutebi M; Bardia A
Ann Surg Oncol; 2015 Oct; 22(11):3418-32. PubMed ID: 26215189
[TBL] [Abstract][Full Text] [Related]
5. Molecular signatures in breast cancer.
Lal S; McCart Reed AE; de Luca XM; Simpson PT
Methods; 2017 Dec; 131():135-146. PubMed ID: 28669865
[TBL] [Abstract][Full Text] [Related]
6. Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?
Ribnikar D; Cardoso F
Am Soc Clin Oncol Educ Book; 2016; 35():e31-8. PubMed ID: 27249737
[TBL] [Abstract][Full Text] [Related]
7. [A Review Multigene Assays for Clinical Utility in Breast Cancer].
Araki K; Ito Y
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1332-1340. PubMed ID: 27899774
[TBL] [Abstract][Full Text] [Related]
8. Gene expression-based prognostic and predictive tools in breast cancer.
Munkácsy G; Szász MA; Menyhárt O
Breast Cancer; 2015 May; 22(3):245-52. PubMed ID: 25874688
[TBL] [Abstract][Full Text] [Related]
9. Molecular predictors of local tumor control in early-stage breast cancer.
Miyamoto DT; Harris JR
Semin Radiat Oncol; 2011 Jan; 21(1):35-42. PubMed ID: 21134652
[TBL] [Abstract][Full Text] [Related]
10. Review of gene-expression profiling and its clinical use in breast cancer.
Stadler ZK; Come SE
Crit Rev Oncol Hematol; 2009 Jan; 69(1):1-11. PubMed ID: 18614375
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX
Curtit E; Mansi L; Maisonnette-Escot Y; Sautière JL; Pivot X
Eur J Surg Oncol; 2017 May; 43(5):921-930. PubMed ID: 28087099
[TBL] [Abstract][Full Text] [Related]
12. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.
Hornberger J; Alvarado MD; Rebecca C; Gutierrez HR; Yu TM; Gradishar WJ
J Natl Cancer Inst; 2012 Jul; 104(14):1068-79. PubMed ID: 22767204
[TBL] [Abstract][Full Text] [Related]
13. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
14. Prognostic applications of gene expression signatures in breast cancer.
Normanno N; De Luca A; Carotenuto P; Lamura L; Oliva I; D'Alessio A
Oncology; 2009; 77 Suppl 1():2-8. PubMed ID: 20130425
[TBL] [Abstract][Full Text] [Related]
15. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
[TBL] [Abstract][Full Text] [Related]
16. New molecular classifications of breast cancer.
Cianfrocca M; Gradishar W
CA Cancer J Clin; 2009; 59(5):303-13. PubMed ID: 19729680
[TBL] [Abstract][Full Text] [Related]
17. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
18. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
19. Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of Prognosis.
Esteva FJ
Clin Adv Hematol Oncol; 2015 Jun; 13(6 Suppl 6):25-31. PubMed ID: 26191943
[TBL] [Abstract][Full Text] [Related]
20. Markers for the identification of late breast cancer recurrence.
Sestak I; Cuzick J
Breast Cancer Res; 2015 Jan; 17(1):10. PubMed ID: 25848913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
